169 related articles for article (PubMed ID: 29947950)
1. Effects of CYP2D6 and CYP3A5 genetic polymorphisms on steady-state pharmacokinetics and hemodynamic effects of tamsulosin in humans.
Kim KA; Park IB; Park JY
Eur J Clin Pharmacol; 2018 Oct; 74(10):1281-1289. PubMed ID: 29947950
[TBL] [Abstract][Full Text] [Related]
2. [Study of allelic variants of the CYP2D6 and CYP3A genes on the effectiveness and safety of tamsulosin therapy in patients with BPH: results of a pilot study].
Abdullaev Sh P; Shatokhin M N; Tuchkova S N; Abdullaev Sh P; Teodorovich O V; Loran O B; Sychev D A
Urologiia; 2023 Dec; (6):5-13. PubMed ID: 38156677
[TBL] [Abstract][Full Text] [Related]
3. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.
Belmonte C; Ochoa D; Román M; Saiz-Rodríguez M; Wojnicz A; Gómez-Sánchez CI; Martín-Vílchez S; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):596-605. PubMed ID: 29325225
[TBL] [Abstract][Full Text] [Related]
4. Effects of CYP2D6*10, CYP3A5*3, CYP1A2*1F, and ABCB1 C3435T polymorphisms on the pharmacokinetics of flecainide in healthy Chinese subjects.
Hu M; Yang YL; Fok BS; Chan SW; Chu TT; Poon EW; Yin OQ; Lee VH; Tomlinson B
Drug Metabol Drug Interact; 2012 Jan; 27(1):33-9. PubMed ID: 22718623
[TBL] [Abstract][Full Text] [Related]
5. Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to CYP2D6*10 allele.
Cho CK; Kang P; Park HJ; Lee YJ; Bae JW; Jang CG; Lee SY
Arch Pharm Res; 2021 Nov; 44(11):1037-1049. PubMed ID: 34751931
[TBL] [Abstract][Full Text] [Related]
6. Effects of diltiazem, a moderate inhibitor of CYP3A4, on the pharmacokinetics of tamsulosin in different CYP2D6 genotypes.
Byeon JY; Lee YJ; Kim YH; Kim SH; Lee CM; Bae JW; Jang CG; Lee SY; Choi CI
Arch Pharm Res; 2018 May; 41(5):564-570. PubMed ID: 29728928
[TBL] [Abstract][Full Text] [Related]
7. Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients.
Kang RH; Jung SM; Kim KA; Lee DK; Cho HK; Jung BJ; Kim YK; Kim SH; Han C; Lee MS; Park JY
J Clin Psychopharmacol; 2009 Jun; 29(3):272-7. PubMed ID: 19440082
[TBL] [Abstract][Full Text] [Related]
8. Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
Suzuki T; Mihara K; Nakamura A; Kagawa S; Nagai G; Nemoto K; Kondo T
Ther Drug Monit; 2014 Oct; 36(5):651-5. PubMed ID: 24682161
[TBL] [Abstract][Full Text] [Related]
9. Effects of CYP2D6, CYP3A5, and ABCB1 gene polymorphisms on the pharmacokinetics of two risperidone long-acting injection microsphere formulations.
Ma L; Xiang Q; Zhao N; Hu C; Fang M; Tan Y; Chen S; Wang Z; Liu P; Sun K; Li Y; Wu F; Tian H; Fang M; Zhao X; Wang G; Cui Y
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jul; 109():110241. PubMed ID: 33400943
[TBL] [Abstract][Full Text] [Related]
10. CYP3A5 but not CYP2D6 polymorphism contributes significantly to the variability in dextropropoxyphene disposition.
Yin OQ; Tomlinson B; Chow MS
J Clin Pharmacol; 2010 Oct; 50(10):1136-41. PubMed ID: 20133509
[TBL] [Abstract][Full Text] [Related]
11. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.
Swaisland HC; Cantarini MV; Fuhr R; Holt A
Clin Pharmacokinet; 2006; 45(6):633-44. PubMed ID: 16719544
[TBL] [Abstract][Full Text] [Related]
12. Effects of CYP3A5 and CYP2D6 genetic polymorphism on the pharmacokinetics of diltiazem and its metabolites in Chinese subjects.
Zheng T; Su CH; Zhao J; Zhang XJ; Zhang TY; Zhang LR; Kan QC; Zhang SJ
Pharmazie; 2013 Apr; 68(4):257-60. PubMed ID: 23700791
[TBL] [Abstract][Full Text] [Related]
13. Association Between the Lower Extremity Deep Venous Thrombosis, the Warfarin Maintenance Dose, and CYP2C9*3, CYP2D6*10, and CYP3A5*3 Genetic Polymorphisms: A Case-Control Study.
Ju S; Gao Y; Cao X; Zhang XF; Yan CC; Liu FT
Genet Test Mol Biomarkers; 2017 Sep; 21(9):539-546. PubMed ID: 28872889
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes.
Fohner A; Muzquiz LI; Austin MA; Gaedigk A; Gordon A; Thornton T; Rieder MJ; Pershouse MA; Putnam EA; Howlett K; Beatty P; Thummel KE; Woodahl EL
Pharmacogenet Genomics; 2013 Aug; 23(8):403-14. PubMed ID: 23778323
[TBL] [Abstract][Full Text] [Related]
15. Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid.
Choi HY; Bae KS; Cho SH; Ghim JL; Choe S; Jung JA; Jin SJ; Kim HS; Lim HS
Pharmacogenet Genomics; 2015 Dec; 25(12):595-608. PubMed ID: 26367500
[TBL] [Abstract][Full Text] [Related]
16. Relationship of CYP2D6, CYP3A, POR, and ABCB1 genotypes with galantamine plasma concentrations.
Noetzli M; Guidi M; Ebbing K; Eyer S; Zumbach S; Giannakopoulos P; von Gunten A; Csajka C; Eap CB
Ther Drug Monit; 2013 Apr; 35(2):270-5. PubMed ID: 23503455
[TBL] [Abstract][Full Text] [Related]
17. Tamsulosin Associated with Interstitial Lung Damage in CYP2D6 Variant Alleles Carriers.
Jessurun NT; Wijnen PA; Bast A; van Puijenbroek EP; Bekers O; Drent M
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316326
[TBL] [Abstract][Full Text] [Related]
18. Association of Polymorphisms of Cytochrome P450 2D6 With Blood Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus.
Lee JY; Vinayagamoorthy N; Han K; Kwok SK; Ju JH; Park KS; Jung SH; Park SW; Chung YJ; Park SH
Arthritis Rheumatol; 2016 Jan; 68(1):184-90. PubMed ID: 26316040
[TBL] [Abstract][Full Text] [Related]
19. ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety.
Gunes A; Spina E; Dahl ML; Scordo MG
Ther Drug Monit; 2008 Oct; 30(5):628-33. PubMed ID: 18708991
[TBL] [Abstract][Full Text] [Related]
20. Tamsulosin exposure is significantly increased by the CYP2D6*10/*10 genotype.
Choi CI; Bae JW; Jang CG; Lee SY
J Clin Pharmacol; 2012 Dec; 52(12):1934-8. PubMed ID: 22245658
[No Abstract] [Full Text] [Related]
[Next] [New Search]
